Carsten Tschöpe1,2,3,4, Sophie Van Linthout5,6,7, Behrouz Kherad8,9,10. 1. Department of Cardiology, Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Berlin, Germany. Carsten.Tschoepe@charite.de. 2. Berliner Zentrum für Regenerative Therapien (BCRT), Campus Virchow Klinikum (CVK), Berlin, Germany. Carsten.Tschoepe@charite.de. 3. Deutsches Zentrum für Herz Kreislaufforschung (DZHK), Berlin, Germany. Carsten.Tschoepe@charite.de. 4. Campus Virchow Clinic, Department of Cardiology, Charité - Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Germany. Carsten.Tschoepe@charite.de. 5. Berliner Zentrum für Regenerative Therapien (BCRT), Campus Virchow Klinikum (CVK), Berlin, Germany. 6. Deutsches Zentrum für Herz Kreislaufforschung (DZHK), Berlin, Germany. 7. Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Föhrerstrasse 15, 13353, Berlin, Germany. 8. Department of Cardiology, Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Berlin, Germany. 9. Campus Virchow Clinic, Department of Cardiology, Charité - Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Germany. 10. Privatpraxis Dr. Kherad, Große Hamburger Strasse 5-11, 10115, Berlin, Germany.
Abstract
PURPOSE OF REVIEW: The current definition of heart failure is mainly based on an inappropriate measure of cardiac function, i.e., left ventricular ejection fraction (LVEF). The initial sole entity, heart failure with reduced ejection fraction (HFrEF, LVEF <40%), was complemented by the addition of heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%) and most recently, heart failure with mid-range ejection fraction (HFmrEF, LVEF 40-49%). Initially, HFpEF was believed to be a purely left ventricular diastolic dysfunction. Pathophysiological concepts of HFpEF have changed considerably during the last years. In addition to intrinsic cardiac mechanisms, the heart failure pathogenesis is increasingly considered as driven by non-cardiac systemic processes including metabolic disorders, ischemic conditions, and pro-inflammatory/pro-fibrotic or immunological alterations. Presentation and pathophysiology of HFpEF is heterogeneous, and its management remains a challenge since evidence of therapeutic benefits is scarce. Up to now, there are no therapies improving survival in patients with HFpEF. RECENT FINDINGS: Several results from clinical and preclinical interventions targeting non-cardiac mechanisms or non-pharmacological interventions including new anti-diabetic or anti-inflammatory drugs, mitochondrial-targeted anti-oxidants, anti-fibrotic strategies, microRNases incl. antagomirs, cell therapeutic options, and high-density lipoprotein-raising strategies are promising and under further investigation. This review addresses mechanisms and available data of current best clinical practice and novel approaches towards HFpEF.
PURPOSE OF REVIEW: The current definition of heart failure is mainly based on an inappropriate measure of cardiac function, i.e., left ventricular ejection fraction (LVEF). The initial sole entity, heart failure with reduced ejection fraction (HFrEF, LVEF <40%), was complemented by the addition of heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%) and most recently, heart failure with mid-range ejection fraction (HFmrEF, LVEF 40-49%). Initially, HFpEF was believed to be a purely left ventricular diastolic dysfunction. Pathophysiological concepts of HFpEF have changed considerably during the last years. In addition to intrinsic cardiac mechanisms, the heart failure pathogenesis is increasingly considered as driven by non-cardiac systemic processes including metabolic disorders, ischemic conditions, and pro-inflammatory/pro-fibrotic or immunological alterations. Presentation and pathophysiology of HFpEF is heterogeneous, and its management remains a challenge since evidence of therapeutic benefits is scarce. Up to now, there are no therapies improving survival in patients with HFpEF. RECENT FINDINGS: Several results from clinical and preclinical interventions targeting non-cardiac mechanisms or non-pharmacological interventions including new anti-diabetic or anti-inflammatory drugs, mitochondrial-targeted anti-oxidants, anti-fibrotic strategies, microRNases incl. antagomirs, cell therapeutic options, and high-density lipoprotein-raising strategies are promising and under further investigation. This review addresses mechanisms and available data of current best clinical practice and novel approaches towards HFpEF.
Authors: Dino B A Tan; Sonia Fernandez; Patricia Price; Martyn A French; Philip J Thompson; Yuben P Moodley Journal: Immunobiology Date: 2014-07-21 Impact factor: 3.144
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Frank Spillmann; Christiane Trimpert; Jun Peng; Lars G Eckerle; Alexander Staudt; Katrin Warstat; Stephan B Felix; Burkert Pieske; Carsten Tschöpe; Sophie Van Linthout Journal: Biochem Biophys Res Commun Date: 2015-09-08 Impact factor: 3.575
Authors: Rutger W van der Meer; Luuk J Rijzewijk; Hugo W A M de Jong; Hildo J Lamb; Mark Lubberink; Johannes A Romijn; Jeroen J Bax; Albert de Roos; Otto Kamp; Walter J Paulus; Robert J Heine; Adriaan A Lammertsma; Johannes W A Smit; Michaela Diamant Journal: Circulation Date: 2009-04-06 Impact factor: 29.690
Authors: Christine Wahlquist; Dongtak Jeong; Agustin Rojas-Muñoz; Changwon Kho; Ahyoung Lee; Shinichi Mitsuyama; Alain van Mil; Woo Jin Park; Joost P G Sluijter; Pieter A F Doevendans; Roger J Hajjar; Mark Mercola Journal: Nature Date: 2014-03-12 Impact factor: 49.962
Authors: Carsten Tschöpe; Christoph Birner; Michael Böhm; Oliver Bruder; Stefan Frantz; Andreas Luchner; Lars Maier; Stefan Störk; Behrouz Kherad; Ulrich Laufs Journal: Clin Res Cardiol Date: 2017-10-10 Impact factor: 5.460
Authors: Christian Mühlfeld; Alexandra Rajces; Martin Manninger; Alessio Alogna; Marie-Christin Wierich; Daniel Scherr; Heiner Post; Julia Schipke Journal: J Anat Date: 2019-11-21 Impact factor: 2.610
Authors: Lars Lind; Jesus A Araujo; Aaron Barchowsky; Scott Belcher; Brian R Berridge; Nipavan Chiamvimonvat; Weihsueh A Chiu; Vincent J Cogliano; Sarah Elmore; Aimen K Farraj; Aldrin V Gomes; Cliona M McHale; Kathleen B Meyer-Tamaki; Nikki Gillum Posnack; Hugo M Vargas; Xi Yang; Lauren Zeise; Changcheng Zhou; Martyn T Smith Journal: Environ Health Perspect Date: 2021-09-24 Impact factor: 9.031